greeksoup/ stock research
Stock research / United States / RDY / Year to 31 March 2025

Dr. Reddy’s Laboratories Limited (RDY) annual results, year to 31 March 2025: revenue INR 325,535 million, from the 20-F

Dr. Reddy’s Laboratories Limited files a 20-F with the SEC once a year, in Indian rupees. In the year to 31 March 2025 it reported revenue of INR 325,535 million ($3.9 billion at the year's average rate), up 16.6% on the year before. Its profit attributable to shareholders was INR 56,544 million, up 1.5%, and diluted earnings per share INR 67.78.

Revenue
INR 325,535 million
+16.6% on the year
FY2018FY2025
Operating margin
22.1%
24.3% a year earlier
FY2018FY2025
Net income
INR 56,544 million
+1.5% on the year
FY2018FY2025
Diluted EPS
INR 67.78
+1.5% on the year
FY2018FY2025

this yearthe year beforeIn Indian rupees as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2024Mar 2025
Revenue279,164325,535
Cost of sales115,557135,107
Gross profit163,607190,428
Research and development22,87327,380
Selling, general and administrative77,20193,870
Operating profit67,72971,843
Finance costs1,7112,829
Profit before tax71,87076,784
Income tax16,18619,539
Profit for the year55,68457,245
Profit attributable to shareholders55,68456,544
Filing20-F20-F
INR million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2024Mar 2025
Diluted EPS66.8067.78
Basic EPS66.9367.88
Filing20-F20-F

INR per ordinary share, as filed.

Cash flow

Year toMar 2024Mar 2025
Cash from operations45,43346,428
Purchase of property, plant and equipment16,40327,504
Free cash flow29,03018,924
Cash from investing-40,283-58,077
Cash from financing-3,76318,911
Depreciation and amortisation14,84117,058
Dividends paid6,6486,662
Filing20-F20-F

INR million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2024Mar 2025
Funded by
Equity attributable to shareholders280,550333,388
Non-controlling interests0.03,778
Borrowings, as filed20,02046,766
Other liabilities86,948109,057
Total equity and liabilities387,518492,989
Owned
Property, plant and equipment76,88697,761
Goodwill4,25311,810
Other intangible assets36,95196,803
Cash and cash equivalents7,10714,654
Trade and other receivables80,29890,420
Inventories63,55271,085
Other assets118,471110,456
Total assets387,518492,989
Filing20-F20-F

INR million, at each fiscal year end.

Ratios on the filed lines

Year toMar 2024Mar 2025
Gross margin58.6%58.5%
Operating margin24.3%22.1%
Net margin19.9%17.4%
Free cash flow margin10.4%5.8%
Return on year-end equity19.8%17.0%
Effective tax rate22.5%25.4%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2025, filed 29 May 2026: the filing. The figures are in Indian rupees as filed.